4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

 St. Anton, Austria    January 28-February 1, 2024

Programme



13:00

Registration

14:30

Opening Remarks

Recent Developments in Synthetic Methodologies and their Impact

Session Chair

Dr Fabrice GALLOU
NOVARTIS PHARMA, Basel, Switzerland
15:00

Organic Reactions in Aqueous Medium enabled by Surfactants (PL01)

Dr Niginia BORLINGHAUS
UNIVERSITY OF KONSTANZ, Konstanz, Germany
15:30

Reagents and Catalysts with Translational Potential (PL02)

Dr Josep CORNELLA COSTA
MAX PLANCK INSTITUTE FOR COAL RESEARCH, Mülheim an der Ruhr, Germany
16:00

Coffee Break

16:30

From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03)

Prof. Timothy NOËL
UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands
17:00

Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04)

Prof. Francesca PARADISI
UNIVERSITY OF BERN, Bern, Switzerland
17:30

Break

17:45

Title to be announced (KL01)

Prof. Darren J. DIXON
UNIVERSITY OF OXFORD, Oxford, United Kingdom
18:45

Welcome Reception

20:15

End of the day

From Underground to Mainstream: Neglected and Novel, Emerging Functional Groups for Drug Discovery

Session Chair

Dr Ulrich LÜCKING
FORX THERAPEUTICS, Basel, Switzerland
08:30

Boron Based Heterocycles and their Application in Drug Discovery (PL05)

Prof. Bhaskar DAS
LONG ISLAND UNIVERSITY, Brooklyn, United States
09:00

“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery (PL06)

Dr Yoshihiro ISHIHARA
VIVIDION THERAPEUTICS, San Diego, United States
09:30

Coffee Break

10:00

Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07)

Prof. Tracey PIRALI
UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy
10:30

New Functional Groups for Synthetic and Discovery Chemistry (PL08)

Prof. Michael WILLIS
UNIVERSITY OF OXFORD, Oxford, United Kingdom
11:00

Outdoor Networking Activities

16:00

Networking Break

16:15

In Silico Prediction of Phase I and II Metabolism: Guiding Optimisation of Drug Metabolism
Company Workshop by Optibrium

Dr Matthew SEGALL
OPTIBRIUM LTD, Cambridge, United Kingdom

Latest Advances and Approaches in Bioconjugation Drug Discovery

Session Chair

Dr Natalia CHERNYAK
MERCK, SHARP & DOHME, South San Francisco, United States
17:00

Bicyclic Peptides as a Novel Therapeutic Modality (PL09)

Dr Mark FRIGERIO
BICYCLE THERAPEUTICS, Cambridge, United Kingdom
17:30

Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10)

Prof. Christian HACKENBERGER
FMP BERLIN, Berlin, Germany
18:00

Coffee Break

18:30

Creating Next-generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11)

Dr Vijaya R. PATTABIRAMAN
BRIGHT PEAK THERAPEUTICS, Basel, Switzerland
19:00

Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12)

Dr Alain WAGNER
CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France
19:30

Poster Session 1 (odd numbers)

20:30

End of the Poster Session

Human Dose Prediction in the Discovery Space

Session Chair

Dr Holger FISCHER
F. HOFFMANN-LA ROCHE LTD., BASEL, Switzerland
08:30

Early Human Dose Predictions in Lead Optimization (PL13)

Dr Johan BYLUND
CTC CLINICAL TRIAL CONSULTANTS AB, Uppsala, Sweden
09:00

Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14)

Dr Gregori GEREBTZOFF
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
09:30

Coffee Break

10:00

SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15)

Dr Andres OLIVARES
F. HOFFMANN-LA ROCHE, Basel, Switzerland
10:30

Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16)

Dr Nicola COLCLOUGH
ASTRAZENECA, Cambridge, United Kingdom
11:00

Outdoor Networking Activities

15:30

Networking Break

Antiviral Drug Discovery

Session Chair

Dr Michael SOFIA
ARBUTUS BIOPHARMA, Doylestown, United States
16:30

Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17)

Dr Helmut BUSCHMANN
AICURIS ANTI-INFECTIVE CURES GMBH, Wuppertal, Germany
17:00

Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18)

Dr Dimitar GOTCHEV
ARBUTUS BIOPHARMA, Doylestown, United States
17:30

Coffee Break

18:00

Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19)

Prof. Priscilla YANG
STANFORD UNIVERSITY, Stanford, United States
18:30

Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20)

Dr Rao KALLA
GILEAD SCIENCES, Foster City, United States
19:00

The Discovery of PAXLOVID (KL02)

Dr Dafydd OWEN
PFIZER, Cambridge, United States
20:30

Conference Dinner

Radical Intermediates in Complex Molecule Synthesis

Session Chair

Prof. Nina HARTRAMPF
UNIVERSITY OF ZURICH, Zürich, Switzerland
08:30

Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21)


Prof. Bart PIEBER
INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (ISTA), Klosterneuburg, Austria
09:00

Recent Adventures in Catalysis and Beyond (PL22)

Prof. Bill MORANDI
ETH ZÜRICH, Zürich, Switzerland
09:30

Coffee Break

10:00

Title to be announced (PL23)

Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
10:30

Attempts to Deliver on the Promise of Natural Product Synthesis (PL24)

Prof. Ryan SHENVI
SCRIPPS RESEARCH, La Jolla, United States
11:00

Outdoor Networking Activities

16:00

Networking Break

16:15

AI for Medicinal Chemists: Novel Compounds Design and Retrosynthesis Prediction
Company Workshop by Iktos

Dr Quentin PERRON
IKTOS, Paris, France

Drug Discovery Tales I

Session Chair

Dr Scott WOLKENBERG
JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States
17:00

NLRP3 Inhibitors for Neurodegenerative Disorders (OC01)

Dr Oscar MAMMOLITI
JANSSEN RESEARCH & DEVELOPMENT, Beerse, Belgium
17:30

Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02)

Dr Isabelle KRIMM
CLB, Lyon, France
17:50

Coffee Break

18:20

Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03)

Dr Christian KUTTRUFF
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany
18:40

Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04)

Dr Luca GOBBI
F. HOFFMANN-LA ROCHE, Basel, Switzerland
19:00

Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05)

Prof. Maria Paola COSTI
UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy
19:20

Poster Session 2 (even numbers)

20:30

End of the Poster Session

Cryo-EM: Applications for Structure-Based Drug Discovery

Session Chair

Dr Katharina DÜRR
OMASS THERAPEUTICS, Oxford, United Kingdom
08:30

Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25)

Prof. Kazuhiro ABE
NAGOYA UNIVERSITY, Nagoya, Japan
09:00

Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26)

Dr Rebecca EBENHOCH
BOEHRINGER INGELHEIM, Biberach, Germany
09:30

Coffee Break

10:00

Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27)

Prof. Jonathan F. FAY
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, Chapel Hill, United States
10:30

Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28)

Dr Harini KRISHNAMURTHY
MERCK, SHARP & DOHME, Blue Bell, United States
11:00

Outdoor Networking Activities

16:00

Networking Break

Drug Discovery Tales II

Session Chair

Dr Scott WOLKENBERG
JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States
17:00

Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06)

Dr Michael G. HAHN
BAYER AG PHARMACEUTICALS, Wuppertal, Germany
17:30

Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07)

Dr Ana MINATTI
AMGEN INC, Copenhagen, Denmark
18:00

Coffee Break

18:30

Title to be announced (OC8)

Dr Frédéric ZECRI
NOVARTIS, Cambridge, United States
19:00

Title to be announced (OC09)

Dr Erik HEMBRE
ELI LILLY AND COMPANY, Indianapolis, United States
19:30

Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03)

Prof. M. Christina WHITE
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States
20:30

Closing Remarks